Impact of age, obesity, and renal impairment on outcomes after autologous stem cell transplantation for patients with newly diagnosed multiple myeloma.
Kelly J GaffneyJonathan K BakosArash VelayatiJames A DavisAswani ThurlapatiErin WeedaAndy MaldonadoKatelynn GrangerColeen ButcherTaylor HerringtonDeidra SmithKimberly GreenBrian T HessHamza HashmiPublished in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2024)
For patients with NDMM undergoing HDT-ASCT, there is no difference in outcomes based on age, BMI, or renal function, and the presence of one or more of these factors should not preclude patients from HDT-ASCT.
Keyphrases
- newly diagnosed
- stem cell transplantation
- multiple myeloma
- high dose
- end stage renal disease
- ejection fraction
- metabolic syndrome
- insulin resistance
- weight gain
- body mass index
- type diabetes
- weight loss
- bone marrow
- peritoneal dialysis
- stem cells
- cell therapy
- mesenchymal stem cells
- patient reported outcomes
- platelet rich plasma